Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development

Journal of Pathology

Volumn 228, Issue 3, 2012, Pages 416-428

  Zhang, Qin ^a,b   He, Xueyan ^a   Chen, Lai ^a   Zhang, Chenxi ^a   Gao, Xiang ^a   Yang, Zhongzhou ^a   Liu, Geng ^a  

^a NANJING UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

congenital heart defects; EMT; endocardial cushion morphogenesis; p53; vasculogenesis

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DENSITY; CELL PROLIFERATION; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; EMBRYO; ENDOCARDIAL CUSHION DEFECT; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE DELETION; GENE DOSAGE; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART DEVELOPMENT; HEART DISEASE; HEART VENTRICLE SEPTUM DEFECT; MALE; MOUSE; NEWBORN DEATH; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION;

ANIMALS; CELL PROLIFERATION; ECHOCARDIOGRAPHY; ENDOCARDIAL CUSHIONS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEART; HEART DEFECTS, CONGENITAL; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MORPHOGENESIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84867578507     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4077     Document Type: Article

References (46)

1. Vogelstein B, Lane D, Levine AJ,. Surfing the p53 network. Nature 2000; 408: 307.
2. Danilova N, Sakamoto KM, Lin S,. Role of p53 family in birth defects: lessons from zebrafish. Birth Defects Res Part C: Embryo Today: Rev 2008; 84: 215-227.
3. Choi J, Donehower LA,. p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci 1999; 55: 38-47.
4. Levine AJ,. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
5. Marine JC, Francoz S, Maetens M, et al., Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-934.
6. Haupt Y, Maya R, Kazaz A, et al., Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
7. Kubbutat MH, Jones SN, Vousden KH,. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
8. Shieh SY, Ikeda M, Taya Y, et al., DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-334.
9. Shvarts A, Steegenga WT, Riteco N, et al., MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15: 5349-5357.
10. Xiong S, Van Pelt CS, Elizondo-Fraire AC, et al., Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A 2006; 103: 3226-3231.
11. Francoz S, Froment P, Bogaerts S, et al., Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A 2006; 103: 3232-3237.
12. Grier JD, Xiong S, Elizondo-Fraire AC, et al., Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 2006; 26: 192-198.
13. Xiong S, Van Pelt CS, Elizondo-Fraire AC, et al., Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation 2007; 115: 2925-2930.
14. Terzian T, Wang Y, Van Pelt CS, et al., Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 2007; 27: 5479-5485.
15. Hoffman JI, Kaplan S,. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39: 1890-1900.
16. Olson EN, Schneider MD,. Sizing up the heart: development redux in disease. Genes Dev 2003; 17: 1937-1956.
17. Boneva RS, Botto LD, Moore CA, et al., Mortality associated with congenital heart defects in the United States: trends and racial disparities, 1979-1997. Circulation 2001; 103: 2376-2381.
18. Wolf M, Basson CT,. The molecular genetics of congenital heart disease: a review of recent developments. Curr Opin Cardiol 2010; 25: 192-197.
19. Bruneau BG,. The developmental genetics of congenital heart disease. Nature 2008; 451: 943-948.
20. Eisenberg LM, Markwald RR,. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 1995; 77: 1-6.
21. Olson EN, Srivastava D,. Molecular pathways controlling heart development. Science 1996; 272: 671.
22. Pierpont ME, Basson CT, Benson DW, et al., Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115: 3015-3038.
23. Botto L, Correa A,. Decreasing the burden of congenital heart anomalies: an epidemiologic evaluation of risk factors and survival. Prog Pediatr Cardiol 2003; 18: 111-121.
24. Jenkins KJ, Correa A, Feinstein JA, et al., Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115: 2995-3014.
25. Nora JJ, Nora AH,. The evolution of specific genetic and environmental counseling in congenital heart diseases. Circulation 1978; 57: 205-213.
26. Butcher JT, Markwald RR,. Valvulogenesis: the moving target. Philos Trans R Soc London Ser B Biol Sci 2007; 362: 1489-1503.
27. Soriano P,. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nature Genet 1999; 21: 70-71.
28. Jacks T, Remington L, Williams BO, et al., Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
29. Kisanuki YY, Hammer RE, Miyazaki J, et al., Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 2001; 230: 230-242.
30. Grier JD, Yan W, Lozano G,. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis 2002; 32: 145-147.
31. Runyan RB, Markwald RR,. Invasion of mesenchyme into three-dimensional collagen gels: a regional and temporal analysis of interaction in embryonic heart tissue. Dev Biol 1983; 95: 108-114.
32. Luna-Zurita L, Prados B, Grego-Bessa J, et al., Integration of a Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation. J Clin Invest 2010; 120: 3493-3507.
33. Markwald RR, Fitzharris TP, Bolender DL, et al., Structural analysis of cell:matrix association during the morphogenesis of atrioventricular cushion tissue. Dev Biol 1979; 69: 634-654.
34. Camenisch TD, Molin DG, Person A, et al., Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 2002; 248: 170-181.
35. Sugi Y, Ito N, Szebenyi G, et al., Fibroblast growth factor (FGF)-4 can induce proliferation of cardiac cushion mesenchymal cells during early valve leaflet formation. Dev Biol 2003; 258: 252-263.
36. Vassilev LT, Vu BT, Graves B, et al., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
37. Wade M, Rodewald LW, Espinosa JM, et al., BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle 2008; 7: 1973-1982.
38. Mone SM, Gillman MW, Miller TL, et al., Effects of environmental exposures on the cardiovascular system: prenatal period through adolescence. Pediatrics 2004; 113: 1058.
39. Aubrecht J, Secretan MB, Bishop AJ, et al., Involvement of p53 in X-ray induced intrachromosomal recombination in mice. Carcinogenesis 1999; 20: 2229-2236.
40. Aolad HM, Inouye M, Darmanto W, et al., Hydrocephalus in mice following X-irradiation at early gestational stage: possibly due to persistent deceleration of cell proliferation. J Radiat Res (Tokyo) 2000; 41: 213-226.
41. Ringshausen I, O'Shea CC, Finch AJ, et al., Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10: 501-514.
42. Shiota M, Izumi H, Onitsuka T, et al., Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 2008; 27: 5543-5553.
43. Chang CJ, Chao CH, Xia W, et al., p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biol 2011; 13: 1467.
44. Kim NH, Kim HS, Li XY, et al., A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol 2011; 195: 417-433.
45. Kim T, Veronese A, Pichiorri F, et al., p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875-883.
46. Thiery JP, Acloque H, Huang RY, et al., Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.